Authors

Latest:

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Brittany Lovely

Managing Editor,

Latest:

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Broadgreen University Hospital NHS Trust

Brock O'Neil, MD

Latest:

Dr. O'Neil on Standard of Care in Muscle-Invasive Bladder Cancer

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.

Brock Schroeder, PhD

Latest:

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

Bruce Cheson, MD, Georgetown Lombardi Comprehensive Cancer Center

Bruce Cheson, MD, Lombardi Comprehensive Cancer Center

Bruce D. Cheson, MD

Latest:

Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Bruce D. Cheson, MD, FACP, FAAAS, Georgetown University Hospital

Bruce E. Johnson, MD, Dana-Farber Cancer Institute

Bruce G. Raphael, MD

Latest:

Dr. Raphael on the Clinical Implications of the CLL14 Trial

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Bruce L. Levine, PhD

Latest:

Dr. Levine on Programmed Anticancer Immunity With T-cell and NK-cell Therapies

Bruce L. Levine, PhD, discusses engineered anticancer immunity with T-cell and natural killer–cell therapies.

Bruce Roth, MD

Latest:

Dr. Roth on the Treatment of Cancers With Bevacizumab

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.

Bruno Daniele, MD

Latest:

Dr. Daniele on Impact of Regorafenib in HCC

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Bruno Sangro, MD, PhD

Latest:

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Bryan A. Mehlhaff, MD

Latest:

Dr. Mehlhaff on the Evolution of the Treatment Landscape in Prostate Cancer

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the ways in which the treatment landscape in prostate cancer has evolved in recent years.

Bryan A. Mehlhaff, MD, Oregon Urology Institute

Bryan Mehlhaff, MD

Latest:

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Bryan R. Haugen, MD

Latest:

Dr. Haugen Describes the 82nd Annual ATA Meeting

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Bryan Schneider, MD

Latest:

Dr Schneider on Targeted Treatment Options in MET Exon 14 Mutated–NSCLC

Bryan Schneider, MD, discusses agents available for use in the targeting of MET exon 14 mutations in non–small cell lung cancer.